Home › Companies › BBOT

BridgeBio Oncology Therapeutics

Market cap $156M 80.3M shares (10-Q, Nov 5, 2026) × $1.94 close Nov 17, 2026

Most recent annual filing: 2026-03-15

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. BBOT pipeline BBO-11818 Ph1 readout2H 2026BBOT pipeline BBO-11818 Ph1 readout, 2H 2026, major
  2. BBO-11818 Ph1 interim4Q 2026BBO-11818 Ph1 interim, 4Q 2026, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (6 active programs)

Discontinued (2)

Capital (as filed)

Cash
$76.5M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$117M Sep 30, 2026
Long-term investments
$121M Sep 30, 2026
Operating cash flow
−$28.4M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$315M cash, runway 2029 per the update of Nov 10, 2026 — the company's own words as read there, not the filed figure

Offering documents (4)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (6)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (6 calls)

Every verdict Biotech Distilled has published on BridgeBio Oncology Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch BridgeBio Oncology (BBOT) - Scientific Deep Dive for BBO-8520, BBO-11818, and BBO-10203 Elegant science and pristine balance sheet, but micro-cohort data and high clinical risk warrant staying on the sidelines until Phase 1b/2 expansion data matures in late 2026.
  2. Watch UPDATE: BridgeBio Oncology (BBOT) - The CSO Takes the Wheel, the FDA Hands Out a Hall Pass Fast Track designation, C-suite reshuffle signaling M&A/pivotal-trial ambitions, and supportive AACR preclinical data modestly strengthen the thesis, but the n remains too small to act.
  3. Watch UPDATE: BridgeBio Oncology (BBOT) - The Internal Combo Leaves the Lab Internal KRAS+PI3Kα combinations are now dosing in patients and execution is on track, but the efficacy dataset is unchanged and the clock is short enough that entry now means buying into a binary.
  4. Watch UPDATE: BridgeBio Oncology (BBOT) - The ATM Arrives Ninety Days Early A $200M ATM filed 90 days before binary readouts makes the downside shape worse without changing the science, keeping the stance on Watch while flagging dilution risk.
  5. Speculative buy speculative UPDATE: BridgeBio Oncology (BBOT) - The n Finally Moved BBO-8520 monotherapy ORR held at 63% as the cohort tripled to 41 patients with no grade 3 liver elevations, materially de-risking the efficacy-erosion failure mode, though the commercial ceiling narrowed to a 2L+ salvage niche and confirmatory data slipped to mid-2027.
  6. Hold UPDATE: BridgeBio Oncology (BBOT) - Trading Below Cash Stock collapsed 75% to trade below cash ($3.93/share net cash vs $2.20 price), but CMO departure ahead of Q4 readouts and lead indication's dependency on third-party Phase 3 wins argue against adding; existing holders should hold through Q4 monotherapy update.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (6 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (31)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 12, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

7 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)